title: Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels.
abstract: We have subverted a receptor-mediated endocytosis event to transport genes into human leukemic cells. By coupling the natural iron-delivery protein transferrin to the DNA-binding polycations polylysine or protamine, we have created protein conjugates that bind nucleic acids and carry them into the cell during the normal transferrin cycle [Wagner, E., Zenke, M., Cotten, M., Beug, H. & Birnstiel, M. L. (1990) Proc. Natl. Acad. Sci. USA 87, 3410-3414]. We demonstrate here that this procedure is useful for a human leukemic cell line. We enhanced the rate of gene delivery by (i) increasing the transferrin receptor density through treatment of the cells with the cell-permeable iron chelator desferrioxamine, (ii) interfering with the synthesis of heme with succinyl acetone treatment, or (iii) stimulating the degradation of heme with cobalt chloride treatment. Consistent with gene delivery as an endocytosis event, we show that the subsequent expression in K-562 cells of a gene included in the transported DNA depends upon the cellular presence of the lysosomotropic agent chloroquine. By contrast, monensin blocks "transferrinfection," as does incubation of the cells at 18 degrees C.
authors.affiliation: Research Institute of Molecular Pathology, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Cotten
authors.forename: F
authors.initials: F
authors.lastname: Längle-Rouault
authors.forename: H
authors.initials: H
authors.lastname: Kirlappos
authors.forename: E
authors.initials: E
authors.lastname: Wagner
authors.forename: K
authors.initials: K
authors.lastname: Mechtler
authors.forename: M
authors.initials: M
authors.lastname: Zenke
authors.forename: H
authors.initials: H
authors.lastname: Beug
authors.forename: M L
authors.initials: ML
authors.lastname: Birnstiel
mesh_terms: D002738:Chloroquine / Q000494:pharmacology; D003035:Cobalt / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology; D006537:Heptanoates / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008156:Luciferases / Q000235:genetics; D008985:Monensin / Q000494:pharmacology; D010587:Phagocytosis; D011107:Polylysine / Q000494:pharmacology*; D000623:Porphobilinogen Synthase / Q000037:antagonists & inhibitors; D011990:Receptors, Transferrin / Q000502:physiology*; D014168:Transferrin / Q000494:pharmacology*; D014170:Transformation, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D006537:Heptanoates; D011990:Receptors, Transferrin; D014168:Transferrin; D011107:Polylysine; D003035:Cobalt; C020804:succinylacetone; D002738:Chloroquine; D008985:Monensin; D008156:Luciferases; D000623:Porphobilinogen Synthase; C018021:cobaltous chloride; D003676:Deferoxamine